Overview

A Study of Advanced or Metastatic Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy and safety of LY2603618 in combination with pemetrexed and any side effects that might be associated with it along with determining the effects of LY2603618 in combination with pemetrexed in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Pemetrexed